On Thursday, TD Cowen maintained a Buy rating on Amgen (NASDAQ:AMGN) shares, with a price target set at $381.00. The firm's stance comes amid positive feedback from Key Opinion Leaders (KOLs) on Amgen's drug candidate, MariTide. These medical experts have indicated that a slower titration approach to dosing could help alleviate tolerability issues, drawing parallels to similar strategies used with other GLP-1 based drugs.
While specifics on Amgen's phase 2 titration process for MariTide are not publicly known, the suggestion is that a one-month titration period should not present any significant challenges. TD Cowen highlighted that the potential for quarterly dosing (QM) combined with a user-friendly autoinjector could make MariTide an attractive option for patients.
The ongoing debate in the medical community regarding GIP agonism versus antagonism remains unresolved. However, both mechanisms of action (MoAs) have shown promising results in terms of weight loss in clinical studies to date. This suggests that regardless of the preferred MoA, the therapeutic outcomes could be beneficial.
Amgen's stock rating and price target by TD Cowen reflect the firm's confidence in the drug's market potential and the company's ability to address the concerns raised about drug tolerability. The reiterated Buy rating indicates a continued positive outlook for Amgen's shares in the market.
In other recent news, Medicare is set to negotiate prices for 10 costly drugs, including Eliquis by Bristol Myers (NYSE:BMY) Squibb and Pfizer (NYSE:PFE), Jardiance by Boehringer Ingelheim and Eli Lilly (NYSE:LLY), and Xarelto by Johnson & Johnson, as part of the Biden administration's Inflation Reduction Act. This move is expected to save the U.S. government $6 billion in the first year, with new prices taking effect in 2026. Moreover, individuals covered by Medicare are projected to save an estimated $1.5 billion on prescription medicines.
In recent developments, Amgen's shares have been a subject of varying analyst opinions. TD Cowen raised its price target for Amgen to $381, maintaining a Buy rating, while RBC Capital increased its price target to $362, maintaining an Outperform rating.
Both firms highlighted the potential of Amgen's drug portfolio, including the promising data for MariTide. However, Wells Fargo downgraded Amgen's stock to Equal Weight, expressing concerns about the risk/reward profile of the shares leading into the year-end Phase 2 data release for MariTide.
These developments are part of recent efforts to control drug prices and highlight the influence of analyst opinions on the market perception of companies like Amgen. As these events unfold, they could potentially impact the future strategies and financial health of the involved companies.
InvestingPro Insights
As TD Cowen maintains a bullish stance on Amgen (NASDAQ:AMGN) with a significant price target of $381.00, it is worth noting some key financial metrics and analyst insights that align with the optimistic view. The market capitalization of Amgen stands robust at $174.15 billion, underlining the company's substantial presence in the biotechnology industry.
Despite trading at a high earnings multiple, with a P/E ratio of 55.26 and an adjusted P/E ratio for the last twelve months as of Q2 2024 at 78.39, Amgen's commitment to shareholder value is evident through its consistent dividend increases over the past 14 years.
Revenue growth remains strong, with a 16.37% increase over the last twelve months as of Q2 2024, suggesting a solid financial performance. This, coupled with a gross profit margin of 63.41%, indicates efficiency in Amgen's operations. Furthermore, the company's stock is trading near its 52-week high, at 93.05% of the peak value, reflecting investor confidence in its prospects.
InvestingPro Tips highlight Amgen's low price volatility and its status as a prominent player in the biotech sector. While 11 analysts have revised their earnings estimates downwards for the upcoming period, it's important to consider the broader financial context provided by the robust revenue and profit margins. For readers seeking more in-depth analysis, additional InvestingPro Tips are available, offering a comprehensive view of Amgen's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.